Day: May 6, 2021

Company announcement No. 9/2021                                                                                                              6 May 2021 Launch of share buyback programmeToday, Netcompany Group A/S (“Netcompany”) announces that the Board of Directors has decided to initiate a share buyback programme of up to DKK 50m for the purpose of meeting Netcompany’s future commitments under its LTIP programmes (RSU). The share buyback programme is launched with reference to the authorisation to acquire treasury shares granted by the general meeting on 22 May 2018. The authorisation is valid until 21 May 2023 and allows Netcompany to acquire shares with a total nominal value of up to 10% of its share capital. The share buyback programme will end no later than 2 June 2021. The share buyback programme will be executed in accordance with...

   6 May 2021First Quarter 2021Operating Result at –1.2 billion euros, EBITDA at -0.6 billion eurosTravel restrictions still impacting the Group’s activityOver the first three months of the year, the Group continued to be negatively impacted by travel restrictions as the whole industry:Revenue at 2.2 billion euros, down 57% compared to last year EBITDA loss at -0.6 billion euros, mitigated due to strict cost control and national partial activity schemes Operating result at -1.2 billion euros, down 0.4 billion euros compared to last year Net income at -1.5 billion euros, after taking interest charges into account Net debt at 12.5 billion euros, up 1.5 billion compared to end of 2020 At 31 March 2021, the Group has 8.5 billion euros of liquidity and credit lines at disposal Early April 2021, first set of balance sheet strengthening...

WISeKey International Holding Ltd Schedules a Conference Call to Discuss the Agenda Items of its 2021 Annual General Meeting of Shareholders Zug, Switzerland, May 6, 2021 – WISeKey International Holding Ltd. (“WISeKey” or “Company”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company, announced today that will hold a conference call on Wednesday, May 12, 2021 at 3:00 pm CET (9:00 am ET) to discuss the agenda items of the proposal our Board of Directors has recommended for shareholder approval at the 2021 Annual General Meeting of Shareholders (“AGM“), scheduled for May 25, 2021. A question and answer session will follow management’s prepared remarks. WISeKey’s shareholders can participate in the event by registering at www.wisekey.com/agm2021. As previously announced, due to the extraordinary situation in connection...

Broadening of the addressable market for Maxigesic IV in Latin America and the Caribbean to 17 countriesMaxigesic IV has potential to combat the opioid epidemic in pain management Liège, Belgium – 6 May 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that its partner for Maxigesic IV, AFT Pharmaceuticals (“AFT”), has extended its existing license and distribution agreement with Pharma Bavaria International for the commercialisation of Maxigesic IV, a novel, patented, non-opioid treatment for post-operative pain, in South America. The extended collaboration further builds on the agreement signed with Pharma Bavaria in February 2020 for the commercialisation of Maxigesic IV in...

  –Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21– –Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21– –Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept– –Actively pursuing new indications and partnerships to maximize value of pipeline candidates–                  GENEVA, Switzerland and BOSTON, MA – May 6, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (ObsEva or the Company), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the quarter ended March 31, 2021 and provided a business update. “The outset...

COMMENTARY FROM MANAGEMENT In Q1 2021, Merko Ehitus posted revenue of EUR 60 million and net profit of EUR 3.4 million, increasing by 7% and 67%, respectively, compared to the previous year. In three months, Merko sold 90 apartments and started construction of more than 560 apartments. The volume of the new construction contracts and secured order book also increased in the first quarter. The management of Merko Ehitus is satisfied with the financial results of the first quarter. Despite the lack of new commercial real estate projects, the construction market in the Baltic Republics is currently quite active. At the same time, prospects remain unclear due to the continuing pandemic and the global rise in material prices. In the first quarter, Merko sold 90 apartments in Tallinn, Tartu, Riga and Vilnius. The apartment market is relatively...

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology researchProjects led by collaborating researchers from the two organizations will focus on autoimmune diseases and inflammatory conditionsPARIS and Palo Alto, CA – May 6, 2021 – Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the two organizations and their scientists will work to advance the understanding of immunology and inflammation through open scientific exchange. Additionally, Sanofi will provide funding and scientific inputs into projects of mutual interest, crossing multiple therapeutic areas including autoimmune diseases and inflammatory conditions. “We look forward to working with some of the most innovative scientists in the human immunology community. Together...

First quarter revenue shows solid return to growth at +14.3%1versus 2020Revenue above 2019 level1 despite COVID-19 pandemic, up 2% at constant exchange rates1 Strong momentum in prescription lenses and optical retail E-commerce up 61% versus 2019 at constant exchange rates1 North America, China and Australia driving the performance Strong balance sheet and free cash flow5 generationCharenton-le-Pont, France (May 6, 2021 – 7:00am) – EssilorLuxottica today announced that consolidated revenue for the first quarter of 2021 totalled Euro 4,060 million, representing a year-on-year increase of 7.3% compared to the first quarter of 2020 (+14.3% at constant exchange rates1). Consolidated revenue grew by 1.9% at constant exchange rates1 compared to the first quarter of 2019. “EssilorLuxottica had a strong start to the year. While the pandemic...

Oslo, 6 May 2021 – DNO ASA, the Norwegian oil and gas operator, today reported operating profit of USD 66 million in the first quarter of 2021, following four quarters of losses triggered by market perturbations from the global Covid pandemic. The turnaround was driven by solid production, cost optimization, higher oil prices and regularization of payments from Kurdistan. The Company stepped up spend early in the year with drilling of new wells and workovers of existing ones in its flagship Tawke license to sustain gross operated production from the Tawke and Peshkabir fields at 112,000 barrels of oil per day (bopd) in the first quarter, up from 110,000 bopd in the previous quarter. Net production attributable to the Company’s interest across the portfolio, including from DNO’s North Sea oil and gas assets, stood just shy of 100,000 barrels...

Saint-Herblain (France), May 6, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,082,762 new ordinary shares, consisting of a public offering of 2,318,881 American Depositary Shares (“ADSs”), each representing two ordinary shares  (the “U.S. Offering”), and a concurrent private placement of 2,445,000 ordinary shares in Europe (including in France) and other countries outside of the United States (the “European Private Placement”, and, together with the U.S. Offering, the “Global Offering”). The aggregate gross proceeds are expected to be approximately $93.5 million, equivalent...